Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Demyelination-related Movement Disorders: Prospective Evaluation of 152 Patients and Comparative Analysis of Patients with and without Spinal Lesions
Multiple Sclerosis
P12 - Poster Session 12 (12:00 PM-1:00 PM)
9-017

To compare demyelination-related movement disorders in patients with and without spinal lesions.


Central demyelination can result in various movement disorders. We have previously shown that spinal cord lesions are the strongest predictor of demyelination-related movement disorders. The difference in movement disorder phenomenology between patients with and without cord lesions is unknown.

This was a pooled analysis of two prospective cohorts with demyelinating diseases. Each patient answered a movement-disorder survey and was clinically evaluated by a movement-disorder specialist. Patients were stratified into two groups according to the presence of spinal lesions and phenomenology was compared between both groups using chi square test. Patients with ganglionic lesions were excluded. Only movement disorders with probable spinal origin according to previously-published criteria were included in patients with spinal lesions. Movement disorders with possible mixed origin were excluded from this group to increase confidence in the spinal origin of these movements.


A total of 152 patients were included (mean age 43.9 years, 63.4% female, 95.4% with multiple sclerosis). There were 93 patients with spinal lesions and 59 without. The most common demyelination-related movement disorders in the entire cohort in a descending order were: tonic spasms, tremor, secondary restless leg syndrome (RLS), myoclonus, focal dystonia, fasciculations, spontaneous clonus, and hyperkeplexia. After excluding  movement disorders with possible mixed origin from the spinal group, the following movement disorders remained more significantly prevalent in patients with spinal lesions than those without spinal lesions: tonic spasms (P=0.013), RLS (P=0.0001), and spontaneous clonus (P=0.016). Tremor was significantly more prevalent in patients without spinal lesions (P=0.032) while dystonia, myoclonus, fasciculations, and hyperkeplexia showed no statistical difference in distribution between the two groups. 


 Tonic spasms, secondary RLS, and spontaneous clonus are strongly-linked to spinal generators while tremor is often supraspinal in origin. Other movement disorders result nearly equally from spinal or supraspial demyelination. 
Authors/Disclosures
Hesham A. Abboud, MD (University Hospitals Cleveland Medical Center)
PRESENTER
Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech . Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alpine Pharma. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cycle Pharma. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axonics. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. The institution of Dr. Abboud has received research support from Genentech . The institution of Dr. Abboud has received research support from Novartis. The institution of Dr. Abboud has received research support from BMS. The institution of Dr. Abboud has received research support from Sanofi-Genzyme. The institution of Dr. Abboud has received research support from The Guthy-Jackson Charitable Foundation. The institution of Dr. Abboud has received research support from UCB. Dr. Abboud has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
Xin Xin Yu, MD (Cleveland Clinic) No disclosure on file
Jeffrey A. Cohen, MD (Cleveland Clinic) Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Convelo. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria. Dr. Cohen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viatris. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PSI. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celltrion.
Hubert H. Fernandez, MD, FÂé¶¹´«Ã½Ó³»­ (Center for Neurological Restoration, Cleveland Clinic) Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intrance. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Fernandez has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Fernandez has received publishing royalties from a publication relating to health care. Dr. Fernandez has received personal compensation in the range of $10,000-$49,999 for serving as a Steering Committee/Advisory Committee Member with Parkinson Study Group.